Morgan Stanley’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
VCM
MCM
TSC
PCM
Morgan Stanley's LUCD Position: Q1 2026 in Review
Morgan Stanley reduced its Lucid Diagnostics (LUCD) stake by 55% in Q1 2026, selling an estimated $72K and leaving 46,037 shares worth $52.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6404.
Morgan Stanley first reported a position in LUCD in Q4 2021 and has held it in 18 quarters since. The position peaked at $537K in Q2 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.
- Morgan Stanley held 46,037 shares of Lucid Diagnostics worth $52.9K as of Q1 2026.
- Morgan Stanley sold 56,561 Lucid Diagnostics shares in Q1 2026, an estimated $72K.
- Lucid Diagnostics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6404 holding.
- Morgan Stanley first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 18 quarters since.
- Morgan Stanley's Lucid Diagnostics position peaked at $537K in Q2 2025.
- 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.